Table 5.
Subgroup analysis of autoantibody level and clinical characteristics of OC patients.
| Variables | n | Anti-LRDD | Anti-STC1 | Anti-FOXA1 | Anti-LRDD or anti-FOXA1 | ||||
|---|---|---|---|---|---|---|---|---|---|
| Positive (%) | P | Positive (%) | P | Positive (%) | P | Positive (%) | P | ||
| Age (year) | |||||||||
| <50 | 52 | 23 (44.2) | 22 (42.3) | 27 (51.9) | 29 (55.8) | ||||
| ≥50 | 84 | 43 (51.2) | 0.430 | 35 (41.7) | 0.941 | 38 (45.2) | 0.448 | 50 (59.5) | 0.666 |
| Family history of tumor | |||||||||
| No | 81 | 39 (48.1) | 34 (42.0) | 39 (48.1) | 48 (59.3) | ||||
| Yes | 36 | 20 (55.6) | 0.460 | 18 (50.0) | 0.420 | 20 (55.6) | 0.460 | 23 (63.9) | 0.636 |
| TNM stage | |||||||||
| Early stage (I + II) | 34 | 17 (50.0) | 13 (38.2) | 15 (44.1) | 19 (55.9) | ||||
| Late stage (III + IV) | 76 | 39 (51.3) | 0.898 | 36 (47.4) | 0.373 | 40 (52.6) | 0.409 | 46 (60.5) | 0.647 |
| Tumor size | |||||||||
| <5 cm | 9 | 4 (44.4) | 5 (44.4) | 5 (55.6) | 5 (55.6) | ||||
| ≥5 cm | 33 | 15 (45.5) | 1.000 | 13 (39.4) | 1.000 | 14 (42.4) | 0.746 | 18 (54.5) | 1.000 |
| Lymph node metastasis | |||||||||
| Positive | 49 | 23 (46.9) | 21 (42.9) | 25 (51.0) | 29 (59.2) | ||||
| Negative | 48 | 23 (47.9) | 0.923 | 18 (37.5) | 0.591 | 22 (45.8) | 0.609 | 27 (56.3) | 0.770 |
| Distant metastasis | |||||||||
| No | 35 | 20 (57.1) | 15 (42.9) | 19 (54.3) | 24 (68.6) | ||||
| Yes | 50 | 17 (34.0) | 0.034 | 18 (36.0) | 0.523 | 19 (38.0) | 0.137 | 26 (52.0) | 0.127 |